Stockscreener 앱 받기
6.54
5.38%
0.22
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
CVKD stock retail sentiment peaks after FDA clears phase 3 path for blood clot drug - MSN
CVKD Earnings History & Surprises | EPS & Revenue Results | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA - TipRanks
Cadrenal Therapeutics Receives FDA Guidance for Pivotal Phase 3 Trial of CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) - Minichart
Cadrenal Advances CAD-1005 Into FDA-Guided Phase 3 Trial - TipRanks
Cadrenal receives FDA guidance to advance CAD-1005 to phase 3 trial - Investing.com
Cadrenal Therapeutics advances CAD-1005 to pivotal Phase 3 after FDA End-of-Phase 2 meeting - TradingView
FDA backs CAD-1005 Phase 3 HIT trial path at Cadrenal (NASDAQ: CVKD) - Stock Titan
Cadrenal Therapeutics Announces End-Of-Phase 2 Meeting with the Fda and Pivotal Phase 3 Registration Path for Cad-1005 in Heparin-Induced Thrombocytopenia - marketscreener.com
[EFFECT] Cadrenal Therapeutics, Inc. SEC Filing - Stock Titan
Cadrenal Therapeutics (CVKD) registers 1.18M shares for resale under S-3 - Stock Titan
Understanding the Setup: (CVKD) and Scalable Risk - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
Cadrenal Therapeutics Incprospectus filed for resale of up to 1.2 million shares of common stock by selling stockholders- SEC filing - marketscreener.com
Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program - Insider Monkey
1.18M shares registered for resale; Cadrenal Therapeutics (NASDAQ: CVKD) - Stock Titan
5 Oversold Biotech Stocks to Invest In Now - Insider Monkey
CVKD Technical Analysis | Trend, Signals & Chart Patterns | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
Retail Surge: What is the next catalyst for Cadrenal Therapeutics IncWeekly Stock Recap & Reliable Price Action Trade Plans - baoquankhu1.vn
FDA Review Uncertainty Puts Cadrenal Therapeutics’ CAD-1005 Phase 3 Timeline and Costs at Risk - TipRanks
Earnings Beat: Can Cadrenal Therapeutics Inc stock double in the next year - baoquankhu1.vn
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting - ADVFN
Is Cadrenal (CVKD) Stock Good for Active Traders | Price at $4.96, Down 0.20%Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Is Cadrenal (CVKD) Stock trading below intrinsic value | Price at $4.86, Up 0.21%Analyst Downgrade - Cổng thông tin điện tử tỉnh Lào Cai
CVKD: Results Show 12-LOX Inhibition Targets Inflammation from Obesity and Type 2 Diabetes - Yahoo Finance
How does Cadrenal (CVKD) Stock perform in rallies | Price at $4.32, Down 7.10%Real Trader Insights - Cổng thông tin điện tử Tỉnh Sơn La
CVKD: Analyst Maintains Buy Rating, But Lowers Price Target | CV - GuruFocus
Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright - TipRanks
Is Cadrenal (CVKD) Stock Breaking Support | Price at $4.65, Down 1.06%Trend Signals - Cổng thông tin điện tử Tỉnh Sơn La
CVKD Stock Analysis: Cadrenal Therapeutics Inc. 4.08% Dip to $4.7 Performance Recap - Xã Thanh Hà
Cadrenal Therapeutics, Inc. (CVKD) stock price, news, quote and history - Yahoo Finance UK
Noble Financial Remains a Buy on Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
How is Cadrenal (CVKD) Stock performing in 2026 | Price at $4.70, Down 4.08%Community Watchlist - Xã Thanh Hà
Cadrenal Therapeutics Announces Warrant Inducement Agreement and Issuance of New Warrants – Form 8-K Filing - Minichart
Cadrenal Therapeutics Enters Warrant Inducement Financing Agreement - TipRanks
Cadrenal Therapeutics Raises $2.5 Million via Warrant Exercise, Issues New $4.50 Warrants - TradingView — Track All Markets
Warrant exercise gives Cadrenal (NASDAQ: CVKD) $2.5M cash - Stock Titan
Cadrenal Therapeutics (NASDAQ: CVKD) amends warrants; registers 590,001 shares - Stock Titan
Cadrenal reports Q4 loss, completes FDA meeting on HIT therapy By Investing.com - Investing.com South Africa
Cadrenal Therapeutics Reports Positive Phase 2 HIT Results and FDA Progress for CAD-1005, Announces Q4 2025 Financials - Minichart
Cadrenal Therapeutics Advances CAD-1005 for HIT Treatment: Clinical Progress, Market Opportunity, and Regulatory Insights - Minichart
Cadrenal Therapeutics 2025 10-K: Net loss $13.24M, EPS $(6.64) - TradingView — Track All Markets
Cadrenal Therapeutics (NASDAQ: CVKD) pivots to CAD-1005 and expands clotting disorder pipeline - Stock Titan
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cadrenal reports Q4 loss, completes FDA meeting on HIT therapy - Investing.com
Cadrenal Therapeutics (NASDAQ: CVKD) widens 2025 loss, advances CAD-1005 toward Phase 3 - Stock Titan
Dividend Watch: Is Cadrenal Therapeutics Inc a strong growth stockFed Meeting & Free Community Supported Trade Ideas - baoquankhu1.vn
Cadrenal Therapeutics, Inc. (CVKD) Eps Diluted (TTM) - zacks.com
CVKD Should I Buy - Intellectia AI
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Technical Reactions to CVKD Trends in Macro Strategies - Stock Traders Daily
0.78%
3.99%
자본화:
|
볼륨(24시간):